2. Search Result
Search Result
Results for "

SMARCA4-Mutant Cancer

" in MedChemExpress (MCE) Product Catalog:
Targets Recommended:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-153361
    YD23

    		PROTACs Epigenetic Reader Domain Cancer
    YD23 is a selective SMARCA2 PROTAC degrader with DC50 values of 64 nM and 297 nM in H1792 cells and H1975 cells. YD23 induces degradation of SMARCA2, which is synthetic lethal to SMARCA4. YD23 reduces chromatin accessibility only in SMARCA4 deficient cells, including cell cycle and cell growth regulatory genes. YD23 selectively inhibits growth of SMARCA4 mutant lung cancer cells. YD23 has potent tumor growth inhibitory activity in SMARCA4-mutant xenografts. YD23 can be used for the study of non-small cell lung cancer (NSCLC) (Pink: SMARCA2 ligand (HY-44012); Blue: CRBN ligand (HY-41547); Black: Linker (HY-175566)) .
    YD23
  • HY-W494890
    SMARCA2-IN-10

    		Epigenetic Reader Domain Cancer
    SMARCA2-IN-10 (Compound 4) is a highly selective SMARCA2 ATPase domain inhibitor (IC50=17.676 μM). SMARCA2-IN-10 induces cell death in SMARCA4-deficient tumors. SMARCA2-IN-10 is promising for research of SMARCA4-mutant non-small cell lung cancer, small cell ovarian carcinoma, and melanoma .
    SMARCA2-IN-10
  • HY-168215
    YDR1

    		PROTACs Epigenetic Reader Domain Cancer
    YDR1 is a potent PROTAC SMARCA2 degrader, with the DC50 of 7.7 nM. YDR1 plays an important role in SMARCA4 mutant cancers(Sturcture Note:(Blue: Cereblon ligand (HY-W087383), Black: linker；Pink: SMARCA2 ligand (HY-44012B)) .
    YDR1

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: